Hostname: page-component-6766d58669-zlvph Total loading time: 0 Render date: 2026-05-16T03:08:35.370Z Has data issue: false hasContentIssue false

Co-Phenylcaine Spray: can we improve the taste? A randomised, double-blind, crossover study

Published online by Cambridge University Press:  07 July 2017

S Bailey*
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Princess Alexandra Hospital, Brisbane, Australia
B Panizza
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Princess Alexandra Hospital, Brisbane, Australia School of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
P Cabot
Affiliation:
School of Pharmacy, Pharmacy Australia Centre of Excellence, University of Queensland, Brisbane, Australia
B Wallwork
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Princess Alexandra Hospital, Brisbane, Australia
*
Address for correspondence: Dr Stuart John Bailey, Department of Otolaryngology – Head and Neck Surgery, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Brisbane, Queensland 4104, Australia Fax: +61 731 762 427 E-mail: stuart.bailey00@gmail.com

Abstract

Objective:

Co-Phenylcaine Forte is a nasal spray routinely prescribed by otolaryngologists in Australia. The taste of Co-Phenylcaine Forte is typically described as unpleasant. This study sought to improve the overall patient experience associated with Co-Phenylcaine Forte by generating a Co-Phenylcaine Forte formulation, referred to as Co-Phenylcaine Zest, which contains an added vanilla flavour and masking agent.

Methods:

Participants were randomised to receive two actuations of Co-Phenylcaine Forte in each nostril followed by two actuations of Co-Phenylcaine Zest, or vice versa. There was a 6–36-hour washout period between each treatment. After the administration of each spray, participants completed a questionnaire to rate various sensory attributes of each formulation on seven-point ordinal scales. Patients reported their overall formulation preference after receiving both treatments.

Results:

A total of 86 participants completed the trial. Seventy-four per cent of patients preferred Co-Phenylcaine Zest, 21 per cent preferred Co-Phenylcaine Forte and 5 per cent had no preference (p < 0.001). The satisfaction score associated with Co-Phenylcaine Zest was 1.22 points greater than with Co-Phenylcaine Forte (p < 0.001).

Conclusion:

A novel formulation of Co-Phenylcaine Forte was created by adding a flavour and a masking agent; this formulation was preferred by most patients.

Information

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable